Bone Biologics Expands Trial Sites
Bone Biologics Corporation announced the expansion of its first-in-human pilot clinical trial for its lead bone graft product, NB1, by adding six hospital sites in Australia. This expansion will double the number of participating centers, likely speeding patient enrollment and surgical scheduling with an anticipated completion by the end of 2026. T…